Cover Image

Insulin‐like growth factor‐1 in cirrhosis is linked to hepatic dysfunction and fibrogenesis and predicts liver‐related mortality

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Lukas Hartl, Michael Schwarz, Benedikt Simbrunner, Mathias Jachs, Peter Wolf, David Josef Maria Bauer, Bernhard Scheiner, Lorenz Balcar, Georg Semmler, Benedikt Silvester Hofer, Nina Dominik, Rodrig Marculescu, Michael Trauner, Mattias Mandorfer, Thomas Reiberger
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
by: Nina Dominik, et al.
Published: (2024)

Prevalence and prognostic value of zinc and selenium deficiency in advanced chronic liver disease
by: Nina Dominik, et al.
Published: (2024)

Biomarkers of Extracellular Matrix Remodelling Are Linked to Severity and Outcome of Advanced Chronic Liver Disease
by: Benedikt Simbrunner, et al.
Published: (2025)

Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis—Authors' reply
by: Lukas Burghart, et al.
Published: (2024)

Indocyanine Green Clearance Correlates With Biomarkers Reflecting Key Disease‐Driving Mechanisms in Advanced Chronic Liver Disease and Predicts Acute‐on‐Chronic Liver Failure and Death
by: Mathias Jachs, et al.
Published: (2025)

Editorial: Recompensation in PBC is good. But is it good enough? Authors' reply
by: Benedikt Silvester Hofer, et al.
Published: (2024)

The deep abdominal ultrasound transducer (DAX) increases the success rate and diagnostic accuracy of shear wave elastography for liver fibrosis assessment in patients with obesity—A prospective biopsy‐controlled study
by: David J. M. Bauer, et al.
Published: (2024)

Letter: Trajectories of Hepatic Function Markers Enable Early Prediction of Hepatic Recompensation
by: Benedikt Silvester Hofer, et al.
Published: (2026)

Editorial: Extracellular Matrix Biomarkers Illuminate the Architecture of Portal Hypertension in End‐Stage Liver Disease—Authors' Reply
by: Mattias Mandorfer, et al.
Published: (2025)

Editorial: Carvedilol Remains the First‐Line Treatment of Portal Hypertension After the CALIBRE Trial
by: Thomas Reiberger, et al.
Published: (2025)

Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non‐Acute Decompensation
by: Lucie Simonis, et al.
Published: (2025)

Editorial: Redefining Decompensation in Cirrhosis—More Than an Academic Playground? Authors' Reply
by: Lucie Simonis, et al.
Published: (2025)

Smoking Aggravates Inflammation, Fibrogenesis, Angiogenesis and Cancer Risk in Patients With Cirrhosis
by: Nina Dominik, et al.
Published: (2025)

Research Communication: The Cumulated Spontaneous Portosystemic Shunts ( SPSS ) Area Decreases After TIPS and Impacts on Prognosis
by: Marlene Hintersteininger, et al.
Published: (2025)

Inflammation remains a dynamic component of portal hypertension in regressive alcohol‐related cirrhosis
by: Benedikt Silvester Hofer, et al.
Published: (2024)

Impact of Underlying Portal Hypertension on Severity and Course of Acute‐On‐Chronic Liver Failure
by: Vlad Taru, et al.
Published: (2025)

Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D
by: Jian Wang, et al.
Published: (2024)

Characterisation and Prognostic Implication of Cholestasis After Burn Injury
by: Lorenz Semmler, et al.
Published: (2026)

Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection
by: Lisa Sandmann, et al.
Published: (2024)

Alcohol Use After TIPS Implantation Significantly Increases the Risk of ACLF and Liver‐Related Death
by: Caroline Schwarz, et al.
Published: (2025)

Letter on ‘Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis’: Authors' Reply
by: Lukas Burghart, et al.
Published: (2026)

Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease
by: Nabil Noureddin, et al.
Published: (2024)

Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed
by: Haibo Jing, et al.
Published: (2024)

Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed. Authors' reply
by: Andrea Martini, et al.
Published: (2024)

Impacts of glucagon‐like peptide‐1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction‐associated steatotic liver disease cirrhosis and type 2 diabetes
by: Mohamed I. Elsaid, et al.
Published: (2024)

Bisphosphonate effectiveness in patients with cirrhosis: An emulated clinical trial
by: Elliot B. Tapper, et al.
Published: (2024)

Prognostication of Liver Disease Patients via the WFUMB ‘Rule‐of‐4’ Algorithm Using SSI ‐ 2D ‐ SWE ‐Based Liver Stiffness Measurement
by: Christian Sebesta, et al.
Published: (2026)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—An emulated clinical trial
by: Mingsi Zhang, et al.
Published: (2024)

Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients
by: Ming‐Lun Yeh, et al.
Published: (2024)

Editorial: Terlipressin and MDRO colonisation in cirrhosis—Is there a causal link?
by: Luciano Revelli, et al.
Published: (2024)

Review article: Evaluation and care of the critically ill patient with cirrhosis
by: Iva Kosuta, et al.
Published: (2024)

Terlipressin therapy is associated with increased risk of colonisation with multidrug‐resistant bacteria in patients with decompensated cirrhosis
by: Marcus M. Mücke, et al.
Published: (2024)

Letter: Post‐Banding Ulcer Bleeding Is More Common With Urgent EBL and Renal Dysfunction
by: Jurij Maurer, et al.
Published: (2026)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—an emulated clinical trial. Authors' reply
by: Elliot B. Tapper, et al.
Published: (2024)

Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients—Authors' reply
by: Linda Henry, et al.
Published: (2024)

Review article: Recent advances in ascites and acute kidney injury management in cirrhosis
by: Danielle Adebayo, et al.
Published: (2024)

Editorial: Novel insights into the prognostic relevance of high‐dose PPI treatment in patients with cirrhosis
by: Dominik Bettinger, et al.
Published: (2024)

Letter: Enhancing cirrhosis management—The critical role of social workers in supporting NAFLD surveillance
by: Senlin Ye, et al.
Published: (2024)

Letter: Shorter duration of intravenous terlipressin for variceal bleeding in patients with cirrhosis—A promising find
by: Leya Nedumannil, et al.
Published: (2024)

Review article: Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors
by: Matthew J. Townsend, et al.
Published: (2024)